ACER THERAPEUTICS INC (ACER) Stock Price, Quote, News and Overview
NASDAQ:ACER - Nasdaq - US00444P1084 - Common Stock - Currency: USD
ACER Quote, Performance and Key Statistics
0.9
+0.03 (+3.41%)
The current stock price of ACER is 0.9 USD. In the past month the price increased by 20%. In the past year, price decreased by -26.83%.
ACER Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 67.21 | 829.40B | ||
| NVO | NOVO-NORDISK A/S-SPONS ADR | 27.44 | 390.99B | ||
| JNJ | JOHNSON & JOHNSON | 16.25 | 390.76B | ||
| AZN | ASTRAZENECA PLC-SPONS ADR | 20.56 | 230.17B | ||
| MRK | MERCK & CO. INC. | 11.71 | 226.40B | ||
| NVS | NOVARTIS AG-SPONSORED ADR | 13.77 | 215.98B | ||
| PFE | PFIZER INC | 8.46 | 149.04B | ||
| SNY | SANOFI-ADR | 13.58 | 136.54B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 48.97 | 113.23B | ||
| GSK | GSK PLC-SPON ADR | 7.78 | 74.77B | ||
| ZTS | ZOETIS INC | 27.1 | 72.39B | ||
| TAK | TAKEDA PHARMACEUTIC-SP ADR | 31.95 | 44.58B |
Related stock screener links
About ACER
Company Profile
Acer Therapeutics, Inc. is a pharmaceutical company, which engages in the acquisition, development, and commercialization of therapies for medical needs. The company is headquartered in Newton, Massachusetts and currently employs 33 full-time employees. The company went IPO on 2006-09-01. The Company’s product pipeline includes OLPRUVA (sodium phenylbutyrate), ACER-801 (osanetant) and EDSIVO (celiprolol). OLPRUVA (sodium phenylbutyrate) for oral suspension is a formulation of sodium phenylbutyrate powder, for the treatment of various inborn errors of metabolism, including urea cycle disorders (UCDs) and Maple Syrup Urine Disease (MSUD). Its ACER-801 (osanetant) is an investigational non-hormonal, neurokinin 3 receptor (NK3R) antagonist for the treatment of asomotor symptoms (VMS), post-traumatic stress disorder (PTSD), and prostate cancer. Its EDSIVO (celiprolol) is a selective adrenergic modulator for the treatment of vascular Ehlers-Danlos syndrome (vEDS) in patients with a confirmed type III collagen (COL3A1) mutation.
Company Info
ACER THERAPEUTICS INC
One Gateway Center (300 Washington St.), Suite 356
Newton MASSACHUSETTS 02458 US
CEO: Chris Schelling
Employees: 33
Company Website: https://acertx.com/
Phone: 18449026100.0
ACER THERAPEUTICS INC / ACER FAQ
What is the stock price of ACER THERAPEUTICS INC today?
The current stock price of ACER is 0.9 USD. The price increased by 3.41% in the last trading session.
What is the ticker symbol for ACER THERAPEUTICS INC stock?
The exchange symbol of ACER THERAPEUTICS INC is ACER and it is listed on the Nasdaq exchange.
On which exchange is ACER stock listed?
ACER stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for ACER THERAPEUTICS INC stock?
8 analysts have analysed ACER and the average price target is 1.53 USD. This implies a price increase of 70% is expected in the next year compared to the current price of 0.9. Check the ACER THERAPEUTICS INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is ACER THERAPEUTICS INC worth?
ACER THERAPEUTICS INC (ACER) has a market capitalization of 22.01M USD. This makes ACER a Nano Cap stock.
How many employees does ACER THERAPEUTICS INC have?
ACER THERAPEUTICS INC (ACER) currently has 33 employees.
What are the support and resistance levels for ACER THERAPEUTICS INC (ACER) stock?
ACER THERAPEUTICS INC (ACER) has a support level at 0.87 and a resistance level at 0.91. Check the full technical report for a detailed analysis of ACER support and resistance levels.
Should I buy ACER THERAPEUTICS INC (ACER) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of ACER, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of ACER, evaluating the profitability, health, valuation and growth aspects
- ACER THERAPEUTICS INC (ACER) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- ACER THERAPEUTICS INC (ACER) Sales and EPS estimates to see what analysts future expectations are.
- ACER THERAPEUTICS INC (ACER) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- ACER THERAPEUTICS INC (ACER) Insider and Institutional Ownership to learn about the owners and their transactions.
- ACER THERAPEUTICS INC (ACER) Stock Chart to make your own analysis
- ACER THERAPEUTICS INC (ACER) Latest news and press-releases to stay up to date.
Does ACER THERAPEUTICS INC (ACER) stock pay dividends?
ACER does not pay a dividend.
When does ACER THERAPEUTICS INC (ACER) report earnings?
ACER THERAPEUTICS INC (ACER) will report earnings on 2024-03-25, after the market close.
What is the Price/Earnings (PE) ratio of ACER THERAPEUTICS INC (ACER)?
ACER THERAPEUTICS INC (ACER) does not have a PE ratio as the earnings reported over the last twelve months were negative (-1.66).
ACER Technical Analysis
ChartMill assigns a technical rating of 6 / 10 to ACER. When comparing the yearly performance of all stocks, ACER turns out to be only a medium performer in the overall market: it outperformed 51.09% of all stocks.
ACER Financial Highlights
Over the last trailing twelve months ACER reported a non-GAAP Earnings per Share(EPS) of -1.66. The EPS decreased by -88.64% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -225.71% | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
ACER Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 80% to ACER. The Buy consensus is the average rating of analysts ratings from 8 analysts.